Stuart Lutzker receives 150,000 ArriVent BioPharma (AVBP) stock options

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. reported that director and President of R&D Stuart Lutzker received a grant of 150,000 stock options to purchase common stock at an exercise price of $22.67 per share on February 2, 2026. These options expire on February 2, 2036.

The options vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on Lutzker’s continued service through each vesting date. Following this grant, he beneficially owns 150,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lutzker Stuart

Role President of R&D

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	150,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 150,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lutzker Stuart

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD, SUITE 100

(Street)

NEWTOWN SQUARE PA 19073

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President of R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.67	02/02/2026		A		150,000		(1)	02/02/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ James Kastenmayer, Attorney-in-Fact for Stuart Lutzker	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ArriVent BioPharma (AVBP) report for Stuart Lutzker?

ArriVent BioPharma reported that director and President of R&D Stuart Lutzker received 150,000 stock options on February 2, 2026. These options give him the right to buy common shares at a fixed exercise price over a long-term vesting period.

How many ArriVent BioPharma stock options were granted to Stuart Lutzker?

Stuart Lutzker was granted 150,000 stock options linked to ArriVent BioPharma common stock. All 150,000 options are reported as beneficially owned directly by him following the transaction, according to the Form 4 derivative securities table provided.

What is the exercise price and expiration date of Stuart Lutzker’s ArriVent BioPharma options?

The granted stock options have an exercise price of $22.67 per share and an expiration date of February 2, 2036. This means he can choose to buy ArriVent BioPharma common stock at $22.67 any time before that expiration, subject to vesting.

How do Stuart Lutzker’s ArriVent BioPharma stock options vest over time?

The options vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments afterward. Vesting is conditioned on his continued service with ArriVent BioPharma through each applicable vesting date, as stated in the footnote.

What roles does Stuart Lutzker hold at ArriVent BioPharma (AVBP) in this Form 4?

The Form 4 lists Stuart Lutzker as both a director and an officer of ArriVent BioPharma, serving as President of R&D. He is not identified as a 10% owner in the filing, based on the relationship boxes that are checked.

Is Stuart Lutzker’s ownership in ArriVent BioPharma options direct or indirect?

The Form 4 shows Lutzker’s 150,000 stock options as held with direct ownership. The ownership form column lists “D” for direct, and there is no separate nature of indirect beneficial ownership disclosed in the derivative securities table.